Organon/$OGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organon
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Ticker
$OGN
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
10,000
ISIN
US68622V1061
Website
Organon Metrics
BasicAdvanced
$2.6B
3.43
$2.88
0.55
$0.86
0.81%
Price and volume
Market cap
$2.6B
Beta
0.55
52-week high
$23.10
52-week low
$8.01
Average daily volume
4.7M
Dividend rate
$0.86
Financial strength
Current ratio
1.672
Quick ratio
0.77
Long term debt to equity
1,648.708
Total debt to equity
1,652.399
Dividend payout ratio (TTM)
39.73%
Interest coverage (TTM)
2.73%
Profitability
EBITDA (TTM)
1,695
Gross margin (TTM)
57.28%
Net profit margin (TTM)
11.92%
Operating margin (TTM)
21.75%
Effective tax rate (TTM)
-11.61%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
6.98%
Return on equity (TTM)
254.24%
Valuation
Price to earnings (TTM)
3.427
Price to revenue (TTM)
0.404
Price to book
4.69
Price to tangible book (TTM)
-0.45
Price to free cash flow (TTM)
4.334
Free cash flow yield (TTM)
23.07%
Free cash flow per share (TTM)
227.50%
Dividend yield (TTM)
8.72%
Forward dividend yield
0.81%
Growth
Revenue change (TTM)
-0.84%
Earnings per share change (TTM)
-29.44%
3-year revenue growth (CAGR)
-0.37%
3-year earnings per share growth (CAGR)
-17.34%
3-year dividend per share growth (CAGR)
10.06%
What the Analysts think about Organon
Analyst ratings (Buy, Hold, Sell) for Organon stock.
Bulls say / Bears say
Organon's fertility business is expected to rebound, benefiting from expanded international operations and improved reimbursement in China. (TipRanks)
The upcoming 5-year indication launch of Nexplanon in October is anticipated to drive sales beyond $1 billion in 2025. (TipRanks)
Nexplanon's demonstrated zero pregnancies in high BMI patients could set a higher standard for generics, potentially exceeding $1.5 billion in peak sales. (TipRanks)
With 75% of Organon's revenue generated outside the U.S., a strengthening USD could create significant currency headwinds. (TipRanks)
A $6 million charge reported in the first quarter may negatively impact the company's financial health. (TipRanks)
VTAMA faces challenges in a heavily managed category, with 40% of plans not covering the drug and high gross-to-net deductions. (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Organon Financial Performance
Revenues and expenses
Organon Earnings Performance
Company profitability
Organon News
AllArticlesVideos
OGN LAWSUIT DEADLINE: Suffer Losses on Organon & Co.? Contact BFA Law before the July 22 Securities Fraud Class Action Deadline (NYSE:OGN)
GlobeNewsWire·9 minutes ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN
GlobeNewsWire·2 days ago
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organon stock?
Organon (OGN) has a market cap of $2.6B as of June 30, 2025.
What is the P/E ratio for Organon stock?
The price to earnings (P/E) ratio for Organon (OGN) stock is 3.43 as of June 30, 2025.
Does Organon stock pay dividends?
Yes, the Organon (OGN) stock pays dividends to shareholders. As of June 30, 2025, the dividend rate is $0.86 and the yield is 0.81%. Organon has a payout ratio of 39.73% on a trailing twelve-month basis.
When is the next Organon dividend payment date?
The next Organon (OGN) dividend payment date is unconfirmed.
What is the beta indicator for Organon?
Organon (OGN) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.